Medindia

X

Pipeline Report: Erectile Dysfunction Market Review H2 2016

Thursday, September 8, 2016 Sexual Health News J E 4
Advertisement

PUNE, India, September 8, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Erectile Dysfunction - Pipeline Review, H2 2016" market research report with comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects.

Complete report on H2 2016 pipeline review of Erectile Dysfunction with 39 market data tables and 16 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/erectile-dysfunction-pipeline-review-h2-2016-market-report.html .

Erectile Dysfunction pipeline therapeutics constitutes close to 31 molecules. Out of which approximately 29 molecules are developed by Companies and remaining by the Universities/Institutes.

It also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 4, 4, 2, 2, 9, 2 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Companies discussed in this Erectile Dysfunction Pipeline Review, H2 2016 report include Apricus Biosciences, Inc., Aytu BioScience, Inc., Biopharm GmbH, Futura Medical Plc, Hanmi Pharmaceuticals, Co. Ltd., Humanetics Corporation, IntelGenx Corp., Ion Channel Innovations, LLC, Mezzion Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Monosol Rx, LLC, NAL Pharmaceuticals Ltd., Palatin Technologies, Inc., Pharmicell Co., Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Suda Ltd and Yungjin Pharm. Co., Ltd. Drug Profiles mentioned in this research report are (PDE-5 Inhibitor + tramadol hydrochloride), alprostadil, AP-102, avanafil, BIO-300, BL-214, Cellgram-ED, fadanafil, HCP-1302, HCP-1303, MED-2002, MED-2005, Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction, pVAX-hSlo, Recombinant Protein for Bone Fracture Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease, sildenafil citrate, Small Molecule to Inhibit PDE5 for Erectile Dysfunction, SUD-003, Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction, T-6932, tadalafil, TF-0092, TPN-729, TR-399, udenafil, VLFIA-330 and YBH-1603.

Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=682912 .

The report also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction and reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Erectile Dysfunction.

Another newly published market research report titled on Male Hypogonadism - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Antares Pharma, Inc., Clarus Therapeutics, Inc., Endo Pharmaceuticals Inc., EndoCeutics, Inc., Ferring International Center S.A., Forendo Pharma Limited, Lipocine Inc., M et P Pharma AG, Merck & Co., Inc., Mereo Biopharma Group Plc, Millennium Pharmaceuticals Inc, Pantarhei Bioscience BV, Repros Therapeutics Inc. and Variant Pharmaceuticals, Inc. Male Hypogonadism Pipeline market research report of 106 pages is available at http://www.rnrmarketresearch.com/male-hypogonadism-pipeline-review-h2-2016-market-report.html .

Explore more reports on Men's Health therapeutics.

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. Tel:  +1-888-391-5441 sales@rnrmarketresearch.com

Connect with Us: 

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Montel Williams Launches Medical Cannabis Company
S
Narayana Health Collaborates with Cisco To Offer S...